Oncoshot in MOU with new Singapore's CRIS
SINGAPORE, April 14, 2022– Oncoshot has signed a memorandum of understanding with the Singapore Clinical Research Institute, the national coordinating body for clinical trials under the newly launched Consortium for Clinical Research and Innovation Singapore (CRIS).
The signing event held last Wednesday was witnessed by guest-of-honour Minister for Health Mr Ong Ye Kung.
Left to right. Top row: Prof John Lim; Mr Ong Ye Kung; Mr Ruslan Enikeev. Bottom row: Dr Danny Soon; Dr Huren Sivaraj. Photo taken from CRIS Symposium 2022.
The symposium was attended by the likes of CRIS Chairman Prof John Lim; Precise Executive Director Prof Patrick Tan; and Singapore Translational Cancer Consortium Executive Director Prof Chng Wee Joo.
This collaboration comes under Project EISE (Enhanced Clinical Trial Initiation, Screening and Enrolment; pronounced ‘easy’) to address two key challenges. Firstly, public healthcare institution (PHI) clinical trial investigators wishing to conduct trials on promising cancer treatments are often limited to the patient pool of their affiliated cancer institutes which may be insufficient. These investigators may not know which other cancer centres to approach for more patients.
Through SCRI, PHI investigators can now request access to anonymised, aggregated information regarding regarding the oncology patient populations in Oncoshot’s network of public and private healthcare institutes.
This includes the National Cancer Centre Singapore, Tan Tock Seng Hospital, Curie Oncology, Icon Cancer Centre, and potentially other leading Australian and Indian research collaborators.
Access to larger populations
Improving access to larger patient populations will enhance and accelerate recruitment for oncology trials led by investigators in Singapore while making it easier for patients in the region to participate in research efforts developed in Singapore.
Secondly, the process of conducting feasibilities and subsequently screening and enrolling patients for cancer clinical trials is presently lengthy, cumbersome, and manual. This collaboration provides clinical trial investigators with a platform to identify patients in a semi-automated manner when leveraging Oncoshot’s trial matching artificial intelligence (AI) platform. The platform provides investigators with a new capability to perform detailed reviews of individual de-identified patient records to determine if they match highly specific trial criteria. The local institutes’ patient databases may also be further enriched with biomarker data to allow trial investigators to improve their chances of identifying suitable patients for these studies.
Partnership with Oncoshot
Through this partnership, SCRI now offers PHI investigators access to aggregated hospital-approved insights based on anonymised, well-annotated, and up-to-date patient data from across Oncoshot’s network of cancer institutes. SCRI will be able to perform feasibility assessments for investigators to determine sufficiently sized eligible patient pools to initiate new trials. /PRNewswire/